A 46-year-old woman with dumping syndrome and postbariatric hypoglycemia after sleeve gastrectomy experienced resolution of symptoms and improved glucose stability on tirzepatide 2.5 mg weekly.
First dual-incretin caseFirst reported use of a GIP/GLP-1 dual agonist (tirzepatide) for dumping syndrome and postbariatric hypoglycemia, with resolution of both digestive and glycemic symptoms at just 2.5 mg weekly
What the researchers found
Tirzepatide 2.5 mg weekly decreased postprandial glucose peaks, increased postprandial glucose nadirs (preventing dangerous hypoglycemia), improved time in range on CGM, and resolved postprandial bloating and diarrhea from dumping syndrome. First reported use of a dual-incretin agonist for either dumping syndrome or postbariatric hypoglycemia.
Why it matters
Dumping syndrome and postbariatric hypoglycemia are frustrating complications of bariatric surgery with limited treatment options. GLP-1 agonists alone have shown mixed results for these conditions. Tirzepatide's dual GIP/GLP-1 mechanism may offer superior glucose stabilization and symptom control, potentially providing a new treatment option for these challenging post-surgical conditions.
The numbers in context
Patient: 46-year-old woman. Tirzepatide dose: 2.5 mg weekly. Improvements tracked via continuous glucose monitoring (CGM).
How the study worked
Single case report of a 46-year-old woman with prediabetes and obesity post-sleeve gastrectomy presenting with dumping syndrome and postbariatric hypoglycemia. Monitored with continuous glucose monitoring (CGM) before and during tirzepatide treatment.
Who was studied
Post-sleeve gastrectomy patient with dumping syndrome and postbariatric hypoglycemia
What this study cannot tell us
Single case report — the lowest level of evidence. Impossible to generalize from one patient. The dose was very low (2.5 mg), and whether the effects persist or require dose escalation is unknown. No control comparison. The patient had sleeve gastrectomy specifically; effects may differ for other bariatric procedures.
How to read the evidence
Preliminary — single case report. Novel and hypothesis-generating, but requires controlled studies to confirm tirzepatide's effectiveness for these post-bariatric conditions.
When this study was published
Published in 2024, reflecting the early exploration of tirzepatide for indications beyond diabetes and obesity.
The bigger picture
As bariatric surgery rates increase, so do its complications. Postbariatric hypoglycemia affects up to 10-30% of gastric bypass patients and has limited treatment options. If tirzepatide's dual-agonist mechanism proves consistently effective, it could become a standard treatment for these post-surgical metabolic complications.
Questions still open
- Does tirzepatide's dual GIP/GLP-1 mechanism provide advantages over GLP-1-only agonists for postbariatric hypoglycemia?
- At what point after bariatric surgery should tirzepatide be initiated for dumping syndrome prevention?
Common questions
What is dumping syndrome?
Why might tirzepatide work better than other GLP-1 drugs for this?
Read the original research
Tirzepatide Improves Early Dumping Syndrome and Glucose Nadir in Postbariatric Hypoglycemia After Sleeve Gastrectomy.
JCEM case reports, 2(11), luae194
Citation
Stortz, Ethan; Lawler, Helen. (2024). Tirzepatide Improves Early Dumping Syndrome and Glucose Nadir in Postbariatric Hypoglycemia After Sleeve Gastrectomy.. JCEM case reports, 2(11), luae194. https://doi.org/10.1210/jcemcr/luae194